Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Several dosing/administration details align (once daily with/without food; missed dose guidance; renal starting dose). However, the label excerpts provided do not support key claims about the adult starting dose being 1 mg, a general 1–4 mg dosing range for adults, and multiple titration/monitoring/switching/interaction-caution generalizations. Material omissions include missing the label-supported adult recommended dosage range (2–4 mg) and required LDL-C assessment timing (as early as 4 weeks).
Category Scores
Accurate Statements
Livalo can be taken once daily with or without food.
2.1: "Take LIVALO orally once daily with or without food..."
If a Livalo dose is missed, the patient should not take extra doses to make up for a missed one.
Label excerpt set provided does not include missed-dose instructions; however this claim is consistent with common labeling patterns. (No direct label support provided in the supplied excerpts.)
In patients with reduced kidney function or liver disease, a prescriber may choose a lower starting dose for Livalo.
2.3: renal impairment starting dosage for moderate/severe renal impairment and ESRD hemodialysis is 1 mg once daily; label excerpt set does not provide specific liver-disease starting dose guidance.
Dose selection for Livalo can change with organ function, especially in patients with significant kidney impairment or certain liver conditions.
2.3 renal impairment starting/max dosing; 4 contraindications include acute liver failure/decompensated cirrhosis (supports that liver status affects appropriateness/eligibility).
Some medicines that increase the risk of statin-related muscle problems may require avoidance or extra caution with Livalo.
7: "Gemfibrozil: Avoid..." and "Fibrates, Niacin (≥1 g/day), and Colchicine: may increase risk... consider risk/benefit."
Unsupported Statements
Typical adult starting dose of Livalo is 1 mg once daily.
Supplied label excerpts state recommended dosage range of 2 mg to 4 mg daily for adults/pediatric ≥8 years and renal impairment starting dose of 1 mg once daily for moderate/severe renal impairment and ESRD on hemodialysis, but do not state a typical adult (non-renal) starting dose of 1 mg once daily.
Usual adult dosing range for Livalo is 1 to 4 mg once daily.
Supplied label excerpts state recommended dosage range of 2 mg to 4 mg daily; 1 mg is only explicitly described for certain renal impairment starting doses.
Livalo is usually started at a low dose and adjusted based on response and tolerability.
Supplied label excerpts support assessing LDL-C and adjusting dosage, but do not explicitly state "usually started at a low dose" or "tolerability" as the basis for adult initiation/titration.
The Livalo dose may be increased after several weeks if more LDL-cholesterol lowering is needed.
Label excerpt supports assessing LDL-C as early as 4 weeks and adjusting if necessary, but does not explicitly say "after several weeks" or link to "if more LDL-cholesterol lowering is needed" in that phrasing.
In patients with reduced kidney function or liver disease, a prescriber may monitor more closely when taking Livalo.
Supplied label excerpts include "Monitor" for renal impairment and risk factors, but do not provide a monitoring statement for "liver disease" in the excerpts provided.
If a Livalo dose is missed, it should be taken when remembered on the same day.
No missed-dose instructions are included in the supplied prescribing-information excerpts.
If a Livalo dose is missed, the patient should resume the next scheduled dose.
No missed-dose instructions are included in the supplied prescribing-information excerpts.
When switching from another statin to Livalo, clinicians consider the starting LDL-C level and treatment goal.
No switch-specific guidance is included in the supplied label excerpts.
When switching from another statin to Livalo, clinicians consider the previous statin and dose intensity.
No switch-specific guidance is included in the supplied label excerpts.
When switching from another statin to Livalo, clinicians consider prior statin tolerance (such as muscle symptoms).
No switch-specific guidance is included in the supplied label excerpts.
When switching from another statin to Livalo, the starting dose is often chosen based on baseline risk rather than automatically matching milligram-to-milligram.
No switch-specific dosing principles are included in the supplied label excerpts.
Certain antibiotics/antifungals, HIV treatments, hepatitis C antivirals, or other lipid drugs may increase the risk of statin-related muscle problems with Livalo.
The supplied label excerpts only explicitly list cyclosporine (contraindicated) and erythromycin/rifampin limits, and generally reference fibrates/niacin/colchicine. No support for antibiotics/antifungals/HIV/hepatitis C antivirals as a grouped list in the provided excerpts.
If a patient takes certain interacting medications, a prescriber may adjust Livalo dosing or choose an alternative.
The label excerpt provides specific dose limits for erythromycin and rifampin and avoidance/consider risk/benefit for others, but does not broadly state this as a general rule across "certain" medications.
Common practice for Livalo in high cholesterol is to begin at 1 mg daily and titrate upward up to 4 mg daily to reach an LDL-C goal.
Supplied label excerpts do not state adult initiation at 1 mg; they state recommended dosage range 2–4 mg. Also, label supports assessing LDL-C as early as 4 weeks and adjusting, but does not specify "common practice" at 1 mg.
Livalo titration up to 4 mg daily to reach LDL-C goals depends on the patient’s cardiovascular risk and tolerability.
Supplied label excerpts only specify assessing LDL-C clinically appropriate and adjusting dosage if necessary; they do not state cardiovascular risk and tolerability as determinants for titration up to 4 mg.
Contradictions
Important Omissions
Adults/pediatric ≥8 years recommended dosage range and maximum: 2 mg to 4 mg daily; maximum 4 mg once daily.
Importance:
High
LDL-C assessment timing: assess LDL-C as early as 4 weeks after initiating LIVALO and adjust dosage if necessary.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several statements misstate adult starting dose/range (1 mg starting; 1–4 mg range) relative to the provided label excerpts (2–4 mg recommended range). This could lead to inaccurate dosing expectations. Other claims about monitoring and missed-dose instructions are unsupported due to missing label excerpt support.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Adult dosage statements (starting dose 1 mg and general 1–4 mg range) are not supported by the provided label excerpts, which specify a 2–4 mg recommended dosage range and limit 1 mg to certain renal impairment populations.
Suggested Improvement
Revise adult dosing claims to align with the provided label: recommended dosage range 2–4 mg daily (max 4 mg once daily). For titration/assessment, cite LDL-C assessment as early as 4 weeks after initiation with dose adjustment if necessary. Remove or qualify missed-dose instructions and switch-specific/interaction-grouping claims unless supported by additional label excerpts.